Neushen - About the company
Neushen is a series A company based in Shanghai (China), founded in 2021 by Mike Poole, Chao Zhang, Lingyun Wu and Joan Shen. It operates as a Developer of drugs for neurological and psychiatric diseases. Neushen has raised an undisclosed amount in funding from Lapam Capital. The company has 3044 active competitors, including 1034 funded and 737 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, Sana Biotechnology and Juno Therapeutics.
Company Details
Developer of drugs for neurological and psychiatric diseases. The company focuses on developing innovative treatments for central nervous system (CNS) disorders with dual platforms of AAV-based gene therapy and a small molecule discovery platform.
- Website
- www.neushen.com
- Email ID
- *****@neushen.com
Key Metrics
Founded Year
2021
Location
Shanghai, China
Stage
Series A
Latest Funding Round
Investors
Ranked
1752nd among 3044 active competitors
Similar Companies
Sign up to download Neushen's company profile
Neushen's funding and investors
Neushen has raised funding over 2 rounds. Its first funding round was on Sep 29, 2022. Its latest funding round was a Series A round on May 19, 2025 for $*****. 3 investors participated in its latest round. Neushen has 5 institutional investors.
Here is the list of recent funding rounds of Neushen:
Date of Funding | Funding Amount | Round Name | Post-Money Valuation | Revenue Multiple | Lead Investors | Other Investors |
|---|---|---|---|---|---|---|
May 19, 2025 | 1698265 | Series A | 7898360 | 7799984 | 3081404 | 9574400 |
Sep 29, 2022 | 2074673 | Seed | 8558661 | 6043918 |
Access funding benchmarks and valuations. Sign up today!View details of Neushen's funding rounds and investors
Neushen's founders and board of directors
Founder? Claim ProfileHere are the details of Neushen's key team members:
- Mike Poole: Co-Founder of Neushen.
- Chao Zhang: Co-Founder & COO of Neushen. Contact Info: 1 email address
- Lingyun Wu: Former Co-Founder of Neushen.
- Joan Shen: Chief Executive Officer and Founder of Neushen.
View details of Neushen's Founder profiles and Board Members
Access Tracxn on any website
Install Tracxn ExtensionOur Google Chrome extension lets you view company details while browsing their websites
Neushen's Competitors and alternates
Top competitors of Neushen include Jazz Pharmaceuticals, Sana Biotechnology and Juno Therapeutics. Here is the list of Top 10 competitors of Neushen, ranked by Tracxn score:
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!
Rank | Company Details | Short Description | Total Funding | Investors | Tracxn Score |
|---|---|---|---|---|---|
1st |  Jazz Pharmaceuticals 2003, Dublin (Ireland), Public | Developer of novel biopharmaceutical medicines for unmet medical needs | $265M | 82/100 | |
2nd |  Sana Biotechnology 2018, Seattle (United States), Public | Developer of genetically engineered cell therapies for multiple disorders | $821M | 75/100 | |
3rd | Juno Therapeutics 2013, Seattle (United States), Acquired | Global biopharmaceutical company discovering, developing, and delivering innovative medicines | $317M | 74/100 | |
4th | C4 Therapeutics 2016, Cambridge (United States), Public | Developer of small molecule drugs for treating cancer | $223M | 74/100 | |
5th |  Bharat Biotech 1996, Hyderabad (India), Early Stage | Manufacturer of vaccines and bio-therapeutic products | $13.7M | 72/100 | |
6th | Pacira 2006, Parsippany Troy Hills (United States), Public | Developer of injectable non-opioid products for post-surgical pain control | $85M | 72/100 | |
7th | Blueprint Medicines 2008, Cambridge (United States), Acquired | Developer of selective kinase inhibitors for patients with genomically defined cancers | $115M | 72/100 | |
8th | Developer of immunotherapeutics for the treatment of cancer and other diseases | $861M | 72/100 | ||
9th | MacroGenics 2000, Rockville (United States), Public | Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease | $126M | 71/100 | |
10th |  iTeos Therapeutics 2011, Cambridge (United States), Acquired | Developer of immunotherapy for treating cancer | $204M | 70/100 | |
1752nd | Developer of drugs for neurological and psychiatric diseases | - | 29/100 |
Get insights and benchmarks for competitors of 2M+ companies! Sign up today!Looking for more details on Neushen's competitors? Click here to see the top ones
Neushen's Investments and acquisitions
Neushen has made no investments or acquisitions yet.
News related to Neushen
•
Get curated news about company updates, funding rounds, M&A deals and others. Sign up today!Are you a Founder ?
FAQs about Neushen
Explore our recently published companies
- BOT Rohstoffe - Wiehl based, 2001 founded, Public company
- Wayca - Gurugram based, 2025 founded, Unfunded company
- Full Support Healthcare - Wellingborough based, 2004 founded, Unfunded company
